28 related articles for article (PubMed ID: 21134110)
1. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience.
Oh MJ; Lee HJ
Clin Mol Hepatol; 2013 Mar; 19(1):51-9. PubMed ID: 23593610
[TBL] [Abstract][Full Text] [Related]
2. Occult hepatitis B: clinical viewpoint and management.
Zobeiri M
Hepat Res Treat; 2013; 2013():259148. PubMed ID: 23533738
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease.
Zachou K; Dalekos GN
Liver Int; 2011 Mar; 31(3):277-9. PubMed ID: 21281426
[No Abstract] [Full Text] [Related]
4. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
[TBL] [Abstract][Full Text] [Related]
8. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection.
Watanabe M; Shibuya A; Tsunoda Y; Danbara M; Ishii R; Ohsaka M; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Horie R; Higashihara M; Koizumi W
Liver Int; 2011 Mar; 31(3):340-7. PubMed ID: 21134110
[TBL] [Abstract][Full Text] [Related]
9. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Muñoz Bertrán E; Pérez Ceballos E; Gómez Espín R; Ortega González I
Gastroenterol Hepatol; 2010 May; 33(5):377-81. PubMed ID: 20363054
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent.
Wijaya I; Hasan I
Acta Med Indones; 2013 Jan; 45(1):61-6. PubMed ID: 23585411
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.
Yeo W; Johnson PJ
Hepatology; 2006 Feb; 43(2):209-20. PubMed ID: 16440366
[No Abstract] [Full Text] [Related]
12. A drug safety evaluation of rituximab and risk of hepatitis B.
Riedell P; Carson KR
Expert Opin Drug Saf; 2014 Jul; 13(7):977-87. PubMed ID: 24821316
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]